Behavioral effects of local microinfusion of pituitary adenylate cyclase activating polypeptide (PACAP) into the paraventricular nucleus of the hypothalamus (PVN).
Pituitary adenylate cyclase activating polypeptide (PACAP) has been implicated in the regulation of several autonomic and neuroendocrine functions. In the hypothalamic paraventricular nucleus (PVN), for example, PACAP-immunoreactive fibers densely innervate corticotropin-releasing hormone (CRH)-containing neurons in the medial parvocellular region, suggesting that PACAP acts to mediate stress responses. Therefore, we examined the behavioral effects of an intra-PVN PACAP injection (25 pmol) in combination with a mild stressor. PACAP or artificial cerebrospinal fluid (aCSF) was microinjected into the PVN (0.25 l) and then animals were restrained or placed in their home cage for 5 min. Exploratory activity (total distance traveled) and scored behaviors (face washing, body grooming, wet dog shakes, and rearing) were observed in a familiar open field for 10 min. In animals receiving aCSF, there were no behavioral differences between restrained and unrestrained groups. For the entire 10-min observation period, animals receiving PACAP, whether restrained or not, displayed elevated face washing and body grooming with decreased locomotor activity and rearing. Among PACAP-injected animals, restrained animals displayed increased body grooming compared to unrestrained animals during the first 2 min in the open field suggesting a summation of the effects of peptide injection and stressor. The observed elevation in grooming is consistent with previous studies reporting similar increases following electrical-, NMDA-, CRH-, or stressor-induced activation of the PVN. Thus, at the level of the PVN, PACAP may act as an excitatory neuropeptide and augment behavioral responses to stressors.
Norrholm
Seth D
SD
Department of Anatomy, College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd., MDC 6, Tampa, FL 33612-4799, United States.
Das
Mahasweta
M
Légrádi
Gábor
G
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D007276:Injections, Intraventricular; D008297:Male; D009414:Nerve Growth Factors / Q000008:administration & dosage / Q000494:pharmacology*; D009479:Neuropeptides / Q000008:administration & dosage / Q000494:pharmacology*; D018377:Neurotransmitter Agents / Q000008:administration & dosage / Q000494:pharmacology*; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects* / Q000502:physiology; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D051381:Rats; D017207:Rats, Sprague-Dawley
C495403:Adcyap1 protein, rat; D009414:Nerve Growth Factors; D009479:Neuropeptides; D018377:Neurotransmitter Agents; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide
J Comp Neurol. 1996 Aug 5;371(4):567-77
8841910
Peptides. 1995;16(8):1511-6
8745066
J Chem Neuroanat. 1996 Oct;11(4):243-56
8951594
J Comp Neurol. 1996 Dec 9;376(2):278-94
8951643
Ann N Y Acad Sci. 1996 Dec 26;805:737-42
8993470
Neuroreport. 1996 Dec 20;8(1):67-70
9051754
Neurosci Res. 1997 Aug;28(4):345-54
9274830
Brain Res. 1997 Oct 31;773(1-2):190-6
9409720
Brain Res. 1998 Apr 20;790(1-2):25-32
9593810
Neurosci Lett. 1998 May 1;246(3):145-8
9792613
Neurosci Biobehav Rev. 1998;23(2):163-77
9884110
Neuroendocrinology. 1999 Mar;69(3):167-80
10087449
Pharmacol Biochem Behav. 1999 Aug;63(4):555-67
10462184
Brain Res Mol Brain Res. 2005 Jul 29;138(1):45-57
15882914
J Neuroendocrinol. 1996 Feb;8(2):137-43
8868261
Neuropharmacology. 2000 Apr 27;39(7):1303-8
10760372
Pharmacol Rev. 2000 Jun;52(2):269-324
10835102
Physiol Res. 2000;49 Suppl 1:S11-7
10984067
Endocr Rev. 2000 Dec;21(6):619-70
11133067
Pharmacol Biochem Behav. 2002 Mar;71(3):457-68
11830180
Eur J Neurosci. 2002 Aug;16(3):381-5
12193178
Neuropeptides. 2004 Feb;38(1):16-20
15003711
Life Sci. 1975 Aug 15;17(4):645-52
171535
J Pharmacol Exp Ther. 1977 Feb;200(2):271-6
557107
Fed Proc. 1981 Apr;40(5):1508-12
6783444
Nature. 1982 May 27;297(5864):331-3
6978997
Neurosci Biobehav Rev. 1986 Fall;10(3):339-70
3095718
Brain Res. 1986 Nov 29;398(2):259-65
3801903
Prog Brain Res. 1986;68:169-90
3550889
Brain Res. 1987 Aug 18;418(1):1-19
3664265
Peptides. 1987 Sep-Oct;8(5):841-4
3501576
Brain Res. 1988 Mar 8;443(1-2):63-9
2834018
Br J Pharmacol. 1989 Mar;96(3):599-608
2470455
Neuroscience. 1990;37(3):603-33
1701038
Brain Res. 1991 Jan 11;538(2):203-10
1849437
Endocrinology. 1991 Nov;129(5):2787-9
1935809
J Comp Neurol. 1991 Nov 22;313(4):563-73
1783681
Physiol Rev. 1992 Jul;72(3):825-52
1320764
Brain Res. 1992 Mar 6;574(1-2):70-6
1638411
Brain Res. 1992 Mar 13;575(1):113-23
1324082
Br J Pharmacol. 1992 Nov;107(3):750-5
1335337
Peptides. 1992 Nov-Dec;13(6):1133-5
1494495
Brain Res. 1993 Jan 29;602(1):57-63
8095427
Neuroendocrinology. 1993 Jun;57(6):1092-6
7901784
Neurosci Biobehav Rev. 1994 Summer;18(2):223-49
8058215
Endocrinology. 1994 Nov;135(5):2177-82
7956940
Behav Brain Res. 1994 Nov 16;65(1):47-55
7880454
Regul Pept. 1995 Jan 26;55(2):133-48
7754101
Front Neuroendocrinol. 1995 Jan;16(1):53-88
7768322
Life Sci. 1995;57(1):69-81
7596223
Physiol Behav. 1995 May;57(5):887-92
7610140
Behav Neurosci. 1995 Oct;109(5):955-64
8554718
Brain Res. 1995 Nov 27;700(1-2):219-26
8624713